Cramer's Mad Money - Navigator Holdings Has Been Unfairly Punished (12/23/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 24, 4:37AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday December 23. Navigator Holdings (NYSE: NVGS ) Has Been Unfairly Punished . Other stock mentioned: Transocean (NYSE: RIG ) With the surge in stocks, it...
RH: 96.97 (-0.16), GD: 141.54 (+0.23), LMT: 196.43 (+0.66), HON: 101.96 (-0.02), RTN: 110.47 (+0.29), NOC: 151.76 (+0.44), KMB: 117.77 (-0.21), XOM: 93.78 (-0.81), IBB: 299.80 (+5.12), VSAT: 63.75 (-0.20), NVGS: 20.00 (+2.10), JACK: 78.82 (-0.17), RIG: 18.77 (-0.37), Q: 59.48 (+0.01), COST: 143.65 (-0.50), WAG: 76.67 (+0.16), ETN: 69.30 (-0.09), MDSO: 47.27 (+0.15), DIS: 94.42 (-0.27), WFC: 55.34 (-0.13), PLKI: 55.50 (+0.01), BA: 131.24 (+1.21), DENN: 9.96 (+0.05), CBRL: 138.16 (+0.46), GILD: 91.29 (+1.84), CVX: 113.47 (-0.48)
Medidata Announces Availability of Patient Profiles Offering
Business Wire - Wed Dec 10, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the availability of its enriched solution for risk-based monitoring (RBM) of clinical trial sites. The company's previously announced acquisition of Patient Profiles, an early-stage software company focused on improving clinical trial data quality, broadens Medidata's best-in-class technology for RBM, a proven methodology for reducing trial costs while providing a higher level of clinical data accuracy and quality.
MDSO: 47.27 (+0.15)
Vital Connect Partners with Medidata to Enhance Clinical Trials with Continuous Vital Sign Monitoring
Business Wire - Tue Dec 09, 11:00AM CST
Vital Connect announced today that its FDA-cleared wearable biosensor, HealthPatch(R) MD, is now available for use in clinical trials in partnership with Medidata (NASDAQ: MDSO), a leading global provider of cloud-based solutions for clinical research in life sciences. HealthPatch(R) MD can be used with Medidata's industry-leading technology platform (Medidata Clinical Cloud(R)) and its mobile app for patient-reported outcomes (Medidata Patient Cloud(R)) to further remote patient monitoring, which has the potential to make clinical trials more efficient.
MDSO: 47.27 (+0.15)
Insider Trading Alert - HAFC, PLCE And MDSO Traded By Insiders
at The Street - Mon Dec 08, 1:49PM CST
Stocks with insider trader activity include HAFC, PLCE and MDSO
HAFC: 21.70 (-0.07), MDSO: 47.27 (+0.15), PLCE: 56.74 (-1.02)
Veeva Stock Jumps After Q3 Earnings, Guidance Beat
at Investor's Business Daily - Wed Nov 26, 10:21AM CST
Shares of Veeva Systems (VEEV), a software provider to the life-science industry, jumped 9% in early trading in the stock market today after the company beat fiscal Q3 estimates and raised its guidance late Tuesday. Veeva's earnings for the quarter...
VEEV: 26.88 (+0.25), MDSO: 47.27 (+0.15), MDRX: 12.87 (-0.13), CERN: 65.10 (-0.21), ATHN: 149.72 (-1.78)
Medidata to Host Financial Analyst Day in New York City on December 8
Business Wire - Mon Nov 24, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it will host a financial analyst day on Monday, December 8, 2014 in New York City. The executive management team will discuss Medidata's long-term growth strategy and showcase the company's innovative platform, the Medidata Clinical Cloud(R).
MDSO: 47.27 (+0.15)
Medidata and TransCelerate BioPharma Inc. Announce Findings of Joint Research Initiative on Clinical Trial Site Monitoring Methods
Business Wire - Wed Nov 19, 7:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the results of a data-driven analysis conducted in collaboration with TransCelerate BioPharma Inc. ("TransCelerate"
MDSO: 47.27 (+0.15)
Medidata Collaborates with GlaxoSmithKline on Mobile Health Initiative to Test Novel Technology for Clinical Trial Optimization
Business Wire - Mon Nov 17, 2:30AM CST
Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced the completion of a method development project conducted in partnership with GlaxoSmithKline plc (GSK) to evaluate the impact of unifying mobile health (mHealth) devices with cloud-based technologies in a clinical trial setting. The joint initiative assessed the capabilities of mHealth tools and evaluated how they could be used to enable a new model for clinical trial conduct that aligns site and patient needs with faster study execution and reduced costs.
MDSO: 47.27 (+0.15), GSK: 42.85 (+0.11)
Investing in Socially Responsible Companies: Medidata Solutions Inc.
Selena Maranjian, The Motley Fool - Motley Fool - Sun Nov 09, 7:10PM CST
Source: Medidata Solutions Being a socially responsible company is not a zero-sum game, where the more socially responsible you are, the worse your financial performance is, and vice versa. Profits don't go out the window when you treat the...
MDSO: 47.27 (+0.15)
Medidata Teams up with Mundipharma Research to Move Clinical Research to the Cloud
Business Wire - Wed Nov 05, 7:30AM CST
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based technology for clinical research in life sciences, today announced that Mundipharma Research Limited (Mundipharma) has adopted Medidata's cloud-based software platform to streamline and accelerate its drug development activities. As part of this agreement, Mundipharma will use the Medidata Clinical Cloud(R) software platform to capture clinical research data electronically and leverage the platform's analytics tools to enhance the speed and safety of its clinical trials.
MDSO: 47.27 (+0.15)
Medidata and PPD Partner to Offer New Approach to Risk-Based Monitoring
Business Wire - Tue Nov 04, 7:30AM CST
Medidata (NASDAQ:MDSO), a leading global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development, LLC (PPD), a global contract research organization (CRO), today announced they are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)--aimed at conducting drug development more intelligently, more quickly and more cost-effectively.
MDSO: 47.27 (+0.15)
Medidata Selected by ASLAN Pharmaceuticals as Enterprise-Wide Technology Platform for Enhancing Clinical Development
Business Wire - Thu Oct 30, 4:30PM CDT
Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that it has signed an enterprise agreement with ASLAN Pharmaceuticals, an oncology-focused biotechnology company. ASLAN's adoption of the industry-leading Medidata Clinical Cloud(TM) supports the company's strategy of maximizing the value of its in-licensed drug portfolio by conducting high quality, efficient clinical development in Asia.
MDSO: 47.27 (+0.15)
Trade-Ideas: Medidata Solutions (MDSO) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Oct 29, 11:12AM CDT
Trade-Ideas LLC identified Medidata Solutions (MDSO) as a "dead cat bounce" (down big yesterday but up big today) candidate
MDSO: 47.27 (+0.15)
Medidata Solutions (MDSO) Stock Falls After Reporting Earnings
at The Street - Tue Oct 28, 2:55PM CDT
Medidata Solutions (MDSO) is falling Tuesday after missing analysts' estimates for revenue and lowering its full year guidance.
MDSO: 47.27 (+0.15)
Medidata Solutions' (MDSO) CEO Tarek Sherif on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:10PM CDT
MDSO: 47.27 (+0.15)
Medidata -8.5% on Q3 miss, full-year guidance cut
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:40AM CDT
MDSO: 47.27 (+0.15)
Medidata Solutions (MDSO) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 6:55AM CDT
MDSO: 47.27 (+0.15)
Medidata meets 3Q profit forecasts
Automated Insights - Tue Oct 28, 5:42AM CDT
NEW YORK (AP) _ Medidata Solutions Inc. (MDSO) on Tuesday reported third-quarter earnings of $161,000.
MDSO: 47.27 (+0.15)
Medidata Solutions misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 5:31AM CDT
MDSO: 47.27 (+0.15)
Medidata Reports Record Third Quarter 2014 Revenues
Business Wire - Tue Oct 28, 5:30AM CDT
--Record subscription revenue of $71.5 million, a 23% year-over-year increase
MDSO: 47.27 (+0.15)